A347850 logo

D&D Pharmatech KOSDAQ:A347850 Stock Report

Last Price

₩34.65k

Market Cap

₩364.4b

7D

5.2%

1Y

n/a

Updated

18 Jul, 2024

Data

Company Financials

D&D Pharmatech Inc.

KOSDAQ:A347850 Stock Report

Market Cap: ₩364.4b

A347850 Stock Overview

A clinical-stage biotech company, develops medicines in South Korea and the United States.

A347850 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance2/6
Financial Health3/6
Dividends0/6

D&D Pharmatech Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for D&D Pharmatech
Historical stock prices
Current Share Price₩34,650.00
52 Week High₩53,900.00
52 Week Low₩25,100.00
Beta0
11 Month Change22.65%
3 Month Changen/a
1 Year Changen/a
33 Year Changen/a
5 Year Changen/a
Change since IPO-5.07%

Recent News & Updates

Recent updates

Shareholder Returns

A347850KR BiotechsKR Market
7D5.2%0.8%-2.4%
1Yn/a26.2%5.4%

Return vs Industry: Insufficient data to determine how A347850 performed against the KR Biotechs industry.

Return vs Market: Insufficient data to determine how A347850 performed against the KR Market.

Price Volatility

Is A347850's price volatile compared to industry and market?
A347850 volatility
A347850 Average Weekly Movement13.1%
Biotechs Industry Average Movement8.0%
Market Average Movement4.9%
10% most volatile stocks in KR Market11.1%
10% least volatile stocks in KR Market2.2%

Stable Share Price: A347850's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine A347850's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2014n/aSeulki Leewww.ddpharmatech.com

D&D Pharmatech Inc., a clinical-stage biotech company, develops medicines in South Korea and the United States. It develops NLY01-PD, NLY01-AD, and NLY01-D that are in Phase II clinical trials for the treatment of Parkinson’s disease (PD), Alzheimer’s disease (AD), and type 2 diabetes; and P4M01, which has completed Phase IIa clinical trials to treat periodontal disease. The company also develops DD01 that is in Phase I clinical trials for the treatment of obesity/diabetes/nonalcoholic steatohepatitis (NASH); TLY012, which is Phase I clinical trials to treat NASH-liver fibrosis, chronic pancreatitis, and systemic sclerosis; PMI03 that is in Phase I clinical trials for the treatment of PD, AD, and neuroinflammation; PMI04, which is in Phase I clinical trials to treat PD, AD, ALS, and depression; and PMI05 and PMI06 that are in Phase I clinical trials for the treatment of oncology and immuno-oncology.

D&D Pharmatech Inc. Fundamentals Summary

How do D&D Pharmatech's earnings and revenue compare to its market cap?
A347850 fundamental statistics
Market cap₩364.37b
Earnings (TTM)₩3.93b
Revenue (TTM)₩18.68b

92.6x

P/E Ratio

19.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A347850 income statement (TTM)
Revenue₩18.68b
Cost of Revenue₩21.35m
Gross Profit₩18.66b
Other Expenses₩14.72b
Earnings₩3.93b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)374.09
Gross Margin99.89%
Net Profit Margin21.06%
Debt/Equity Ratio2.8%

How did A347850 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.